Zelluna ASA

Zelluna ASA: New share capital registered

Oslo, Norway, 8 December, 2025: Reference is made to the stock exchange

announcement made by Zelluna ASA (the "Company") on 3 November 2025 regarding

the successful private placement of 5,500,000 new shares (the "Private

Placement"), divided on a first tranche of 3,729,774 new shares and a second

tranche of 1,770,226 new shares ("Tranche 2"), and the allocation of 315,639 new

shares in the retail offering carried out via the PrimaryBid platform.

The share capital increase pertaining to the issuance of the 1,770,226 new

shares in Tranche 2 has now been registered with the Norwegian Register of

Business Enterprises. The Company's new share capital is NOK 26,269,801 divided

into 26,269,801 shares, each with a par value of NOK 1.

For further information, please contact:

Namir Hassan, CEO, Zelluna ASA

(https://www.globenewswire.com/Tracker?data=Z8lLmV-

B1LwB9B24FA19vFGXbMF1uWuib96CE8rRZizu90Na0VH2EMuvz0ZT8R_M3cGZvcz7cwsWR7BQXKOGGup

zjLAZA3udqBHb-dOQPqaJliih1_RADUlCCR7Hs9ov)

Phone: +44 7720 687608

Hans Vassgård Eid, CFO, Zelluna ASA

(https://www.globenewswire.com/Tracker?data=xw_BegYpiBk6hexlBFgOsk7tj2DC2GZ9wD-

xUL0RvSOAFKyBsXJCyN1-

yeYF_y4PiN7qNCFrqSFIFzf4Oy78pFiEzLGlsgS23tV0HELOjUoSe5eLjAVVxGWn_gS6AJdD)

Phone: +47 482 48632

About Zelluna ASA

Zelluna ASA (OSE: ZLNA) is a biotechnology company pioneering the development of

allogeneic 'off-the-shelf' T Cell Receptor-based Natural Killer (TCR-NK) cells

for the treatment of cancer. The company's platform combines the innate killing

power of NK cells with the precision targeting of TCRs, designed to address the

limitations of current cell therapies, particularly in solid tumours. Zelluna's

proprietary manufacturing process enables scalable, cost-effective production of

TCR-NK cell therapies, with potential for broad patient accessibility. The

company's lead program, ZI-MA4-1, targets the MAGE-A4 tumour antigen and is

expected to enter clinical trials in 2026. Zelluna is headquartered in Oslo,

Norway.

AI Terminal